Global Cell and Gene Therapy CDMO Market is estimated to witness a significant CAGR of 25% to reach $5 billion by 2025
Robust CGT pipeline with growing number of product approvals, strong support from large pharma and biotech, and consistent investor enthusiasm (~$20 bn raised in 2020) is set to boost the demand for CGT services. A growing pipeline of therapies are nearing regulatory decisions. Out of 1,220 ongoing clinical trials in 2020, 152 were in Phase 3 — FDA and EMA predict approval of 10-20 cell and gene therapies each year by 2025. Rising Demand for Full-service/One-stop-shop CDMOs Full-service CDMOs that can assist with both development and manufacturing are in utmost demand. Much of the CGT development as of late has been from smaller biotech companies or research universities who rely on CDMOs from preclinical development through packaging. “There is growing demand for Cell and Gene Therapy CTDMOs who can offer integrated development, manufacturing, and testing services. For CGT companies, outsourcing manufacturing and testing operations to a capable CTDMO can reduce development timel...